Phase II Study: Frontline Cytarabine and Idarubicin + Nivolumab in Newly Diagnosed AML

Slideset - Study reported median event-free survival of 8.3 months in patients receiving nivolumab plus cytarabine and idarubicin with manageable safety profile.

Source: Clinical Care Options Leukemia - December 19, 2017 Category: Hematology Source Type: research